Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
ProShares UltraShort Energy
DUG
5
ProShares Ultra Energy
DIG
US Stock MarketDetailed Quotes
Insight Molecular Diagnostics (IMDX)
- 4.590
- -0.490-9.65%
Close Jul 13 16:00 ET
- 4.390
- -0.200-4.36%
Post 16:16 ET
148.21MMarket Cap-3.04P/E (TTM)
5.020High4.390Low569.59KVolume5.020Open5.080Prev Close2.64MTurnover5.70%Turnover RatioLossP/E (Static)32.29MShares8.51052wk High-13.87P/B45.88MFloat Cap2.33052wk Low--Dividend TTM10.00MShs Float204.800Historical High--Div Yield TTM12.40%Range %1.922Historical Low4.642Avg Price1Lot Size
Insight Molecular Diagnostics (IMDX) News
IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper
IMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
Insight Molecular Diagnostics Shareholders Back Board and Incentive Plan
Favorable Head-to-Head Data on IMDx's GraftAssure With Competing NGS Assay Published in Clinical Chemistry
IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
IMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
12 Health Care Stocks Moving In Friday's After-Market Session
Insight Molecular Diagnostics Balances Progress and Cash Burn
BTIG Maintains Insight Molecular Diagnostics(IMDX.US) With Hold Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (AQST), Sangamo Therapeutics (OtherSGMO) and Insight Molecular Diagnostics (IMDX)
OncoCyte's Earnings Call Maps Risky Path to Launch
Insight Molecular Diagnostics Shares Are Trading Higher. The Company Reported Its Q1 Financial Results.
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX)
Insight Molecular Diagnostics Maintained at Buy as GraftAssure Platform Gains Traction; $9 Price Target Reaffirmed
Earnings Call Summary | Insight Molecular Diagnostics(IMDX.US) Q1 2026 Earnings Conference
Insight Molecular Diagn 1Q Loss/Shr 12c >IMDX
Insight Molecular Diagn 1Q Rev $32,000 >IMDX
Insight Molecular Diagnostics | 10-Q: Quarterly report
Insight Molecular Diagnostics Inc. GAAP EPS of -$0.12 Beats by $0.14, Revenue of $0.32M Beats by $0.09M
Market Insights
China Concept Stocks China Concept Stocks
Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation. Chinese Concept Stocks refer to companies with core operations and revenue from Mainland China, listed on U.S. exchanges. They serve as a key bridge for global investors to access China's growth and innovation.
View More
Hot Topics Hot Topics
Middle East conflict spreads to the stock market! How should investors respond?
On Monday, tensions between the U.S. and Iran over the Strait of Hormuz escalated further. Trump announced plans to reinstate a naval blocka
牛牛課堂
Mar 4 17:09
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
牛牛課堂
Mar 18 18:18
Hormuz, Term Structure and USO: Navigating the Energy Storm